Clinical Trial: Intraocular Bevacizumab (Avastin) for Rubeosis Iridis

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma<

Brief Summary: Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers. Bevacizumab may have a role in treating ocular disorders involving fibrovascular proliferation. To determine whether intraocular bevacizumab decreases rubeosis iridis in patients with neovascular glaucoma.

Detailed Summary:
Sponsor: Instituto de Olhos de Goiania

Current Primary Outcome: Intraocular Bevacizumab (Avastin) for Rubeosis Iridis [ Time Frame: Compare results ]

RI was investigated prospectively by iris biomicroscopy. An expanded informed consent with an off-label use waiver and explanation letter was reviewed with all patients


Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Instituto de Olhos de Goiania

Dates:
Date Received: November 8, 2007
Date Started: November 2006
Date Completion:
Last Updated: November 25, 2011
Last Verified: November 2011